In Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, the major investigators working in this rapidly advancing field join together under the aegis of A. Michael Lincoff and Eric J. Topol to provide the first comprehensive overview of the preclinical and clinical development of the glycoprotein IIb/IIIa receptor antagonists. These acknowledged experts elucidate the theoretical basis for the inhibition of platelet aggregation in the treatment of coronary syndromes, present and synthesize evidence for the efficacy of glycoprotein IIb/IIIa blockade in inhibiting ischemic complications of both coronary intervention and acute coronary syndromes, and provide guidelines for the use of this novel class of agents in the clinical management of cardiovascular disease. They also compare the pharmacology and clinical efficacy of the currently available glycoprotein IIb/IIIa receptor inhibitors and speculate about further potential applications of these agents in the treatment of vascular disease.
Written by the scientists and physicians who discovered and characterized this important new class of receptors, invented the first IIb/IIIa agents, and conducted the definitive clinical trials, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease offers the most complete and authoritative review of these powerful new therapeutics available today.

Klappentext

Zur Zeit liegt uns keine Inhaltsangabe vor.

Inhalt

Part I. Basic Principles. Thrombosis in Acute Coronary Syndromes and Coronary Interventions, Thaddeus R. Tolleson and Robert A. Harrington. Mechanisms of Platelet Adhesion, Edward F. Plow. Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis, Debbie A. Law and David R. Phillips. Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Select Agents. Barry S. Coller Part II. Glycoprotein IIb/IIIa Blockade During Coronary Intervention. Abciximab in Coronary Intervention: The EPIC, EPILOG, EPISTENT Trials, A. Michael Lincoff. Eptifibatide in Coronary Intervention: The IMPACT Trials, Conor O'Shea and James E. Tcheng. Tirofiban in Coronary Intervention: The RESTORE Trial, Mohamed Y. Salame, Spencer B. King III, and Nicolas A. Chronos. Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot and the CAPTURE Study, Marcel J. B. M. van den Brand and Maarten L. Simoons. Overview of the Glycoprotein IIb/IIIa Interventional Trials, A. Michael Lincoff and Eric J. Topol. Part III. Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes. Unstable Angina: PURSUIT, PARAGON, PRISM, and PRISM Plus, David J. Moliterno and Harvey D. White. The Use of Glycoprotein IIb/IIIa in Acute Myocardial Infarction, Adam B. Greenbaum, Robert A. Harrington, and E. Magnus Ohman. Part IV. Practical Issues and Future Applications. Economics of Glycoprotein IIb/IIIa Inhibition, Daniel B. Mark. Monitoring Platelet Aggregation, Neal S. Kleiman, Wojciech Mazur, and Nikki Graziadei. Oral Platelet Glycoprotein IIb/IIIa Blockade, Dean J. Kereiakes and Christopher P. Cannon. Cerebrovascular Aspects of Glycoprotein IIb/IIIa Inhibitors, Cathy A. Sila. The Future of Glycoprotein IIb/IIIa Inhibitors, Robert M. Califf and David F. Kong.